160 related articles for article (PubMed ID: 24723227)
21. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
22. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
23. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
24. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
25. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
26. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts.
Feng MX; Hong JX; Wang Q; Fan YY; Yuan CT; Lei XH; Zhu M; Qin A; Chen HX; Hong D
Sci Rep; 2016 Jan; 6():19074. PubMed ID: 26743690
[TBL] [Abstract][Full Text] [Related]
27. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.
Biswas S; Nyman JS; Alvarez J; Chakrabarti A; Ayres A; Sterling J; Edwards J; Rana T; Johnson R; Perrien DS; Lonning S; Shyr Y; Matrisian LM; Mundy GR
PLoS One; 2011; 6(11):e27090. PubMed ID: 22096521
[TBL] [Abstract][Full Text] [Related]
28. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
30. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
31. Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts.
Zhu S; Moore TW; Morii N; Howard RB; Culver D; Arrendale RF; Reddy P; Evers TJ; Zhang H; Sica G; Chen ZG; Sun A; Fu H; Khuri FR; Shin DM; Snyder JP; Shoji M
Curr Cancer Drug Targets; 2014; 14(4):380-93. PubMed ID: 24628271
[TBL] [Abstract][Full Text] [Related]
32. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice.
Yan W; Wang TY; Fan QM; Du L; Xu JK; Zhai ZJ; Li HW; Tang TT
Acta Pharmacol Sin; 2014 Jan; 35(1):124-34. PubMed ID: 24384612
[TBL] [Abstract][Full Text] [Related]
33. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Pivetta E; Scapolan M; Pecolo M; Wassermann B; Abu-Rumeileh I; Balestreri L; Borsatti E; Tripodo C; Colombatti A; Spessotto P
Breast Cancer Res; 2011 Oct; 13(5):R105. PubMed ID: 22032644
[TBL] [Abstract][Full Text] [Related]
34. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
35. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
36. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
[TBL] [Abstract][Full Text] [Related]
37. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.
Pollari S; Käkönen RS; Mohammad KS; Rissanen JP; Halleen JM; Wärri A; Nissinen L; Pihlavisto M; Marjamäki A; Perälä M; Guise TA; Kallioniemi O; Käkönen SM
Mol Cancer Res; 2012 May; 10(5):597-604. PubMed ID: 22522458
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
40. Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling.
Hsieh CJ; Kuo PL; Hou MF; Hung JY; Chang FR; Hsu YC; Huang YF; Tsai EM; Hsu YL
Int J Oncol; 2015 Feb; 46(2):555-62. PubMed ID: 25421824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
